Navigation Links
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's advanced pharmacodynamic biomarker assay technology provides reliable predictive data of clinical response. This study showed the benefit of treating aggressive head and neck cancer patients with a combination of targeted molecular drugs.

Cancer treatment is evolving from the use of highly toxic systemic compounds to targeted molecular drugs that are safer and faster acting because they aim only at cancer cell structures and their bio-mechanisms. Pharmacodynamics is an evolving field that encompasses the study of the biochemical and physiological effects of drugs, the mechanisms of drug action and the relationship between drug concentration and biological effect.

ApoCell has developed an analytical tool, the PDx Index(TM) (Pharmaco-Diagnostic Index), which indicates the likelihood of whether a targeted therapy will elicit a clinical response. The predictive index in this study was derived by comparing the biochemical state of a cancer cell receptor that is critical to the process of angiogenesis or vascularization of tumors. This PDx Index(TM) of patients with head and neck cancer showed a direct correlation between the drug regimen and patient response. This new technology is applicable to predicting the clinical outcome of most molecular targeted cancer drugs.

Dr. Darren Davis, ApoCell's President and CEO comments, "We have developed the PDx Index(TM) methodology to give drug developers, clinical investigators and oncologists a quantitative tool to predict effectiveness of cancer drug treatment. Recent research has demonstrated that different individuals respond differently to the same cancer drug therapy. By knowing a patient's PDx Index(TM) score ahead of time, the physician can prescribe the right drug treatment that has the highest probability of success for that individual."

About ApoCell, Inc.

ApoCell was founded in 2004 to commercialize biomarker technologies that were developed at the University of Texas M.D. Anderson Cancer Center. This proprietary method monitors the effectiveness of cancer drugs by measuring biomarker expression patterns in patient specimens. ApoCell provides analytical biomarker services to pharmaceutical and biotechnology companies, and clinical researchers in academia and government to assist them in developing new therapeutic agents. ApoCell's technology has been tested in 38 clinical studies with over 11,000 specimens on 28 investigational drugs including six FDA approved cancer drugs. ApoCell's molecular-based diagnostics have application in oncology and other diseases. For more information, please visit www.apocell.com.

Contact

ApoCell, Inc., Houston
Darren Davis, 713-440-6070


'"/>




Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/2/2017)... , Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short ... to kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 18, 2017 , ... Moore Insurance, a Houston area agency ... is launching a regional charity effort to provide publicity assistance and generate donations ... Tumor Foundation (PBTF) has raised nearly $30 million in donations that has been ...
(Date:8/18/2017)... ... August 18, 2017 , ... Goss & Associates ... residential and commercial clients in the greater Houston region, is helping locally recognized ... the fight against cancer. , Founded by Tony and Amber Bender after losing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become a ... conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
(Date:8/18/2017)... ... 18, 2017 , ... Inc. magazine has ranked American Specialty Health, Incorporated (ASH) ... nation's fastest-growing private companies. This marks the eighth time in the last nine years ... year’s ranking reflects ASH’s 76 percent overall revenue growth from 2013 ($239 million) through ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about saving the ... Diane is from Southwest Nebraska where she was raised on a farm. As ... story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ have always ...
Breaking Medicine News(10 mins):